Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of cixutumumab when given
together with sorafenib tosylate in treating patients with advanced liver cancer. Monoclonal
antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Sorafenib tosylate may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with
sorafenib tosylate may kill more tumor cells.